科倫藥業(002422.SZ)：優化川寧生物股東結構及資本結構 推動其分拆上市工作
格隆匯9月25日丨科倫藥業(002422.SZ)公佈，公司第六屆董事會第三十三次會議決議，審議通過了《關於轉讓成都科倫寧禾企業管理合夥企業(有限合夥)財產份額的議案》。
為推動子公司伊犁川寧生物技術股份有限公司(“川寧生物”)分拆上市工作，同意公司全資子公司成都科倫川智企業管理有限公司(“科倫川智”)將所持有的成都科倫寧禾企業管理合夥企業(有限合夥)(“科倫寧禾”)0.1%的合夥份額(對應出資額1萬元)轉讓給上海東證錫毅股權投資基金合夥企業（有限合夥)(“東證錫毅”)，東證錫毅成為科倫寧禾的普通合夥人；同意公司將所持有的科倫寧禾39.9%的合夥份額（對應出資額399萬元）轉讓給東證錫毅，並將所持有的科倫寧禾60%的合夥份額(對應出資額600萬元)轉讓給“證券行業支持民企發展系列之海通證券資管1號FOF單一資產管理計劃”(管理人“上海海通證券資產管理有限公司”，“資管計劃”)，資管計劃成為科倫寧禾的有限合夥人，並在辦理合夥人的工商登記手續時登記至其管理人上海海通證券資產管理有限公司名下。
鑑於科倫寧禾為持股企業，其擁有的資產為持有川寧生物5%的股權，參考開元資產評估有限公司就川寧生物以2019年12月31日為評估基準日出具的《資產評估報告》(開元評報字[2020]191號)確定的評估值以及川寧生物截至2020年6月30日的賬面淨資產值，由各方就川寧生物5%的股權協商作價2.35億元。
考慮到科倫寧禾應向公司支付其自公司受讓川寧生物5%股權的股權轉讓款，為此，東證錫毅、資管計劃以支付合夥份額轉讓款和通過增資科倫寧禾償還公司債務方式支付2.35億元對價，即東證錫毅、資管計劃分別以400萬元和600萬元受讓公司轉讓的科倫寧禾合夥份額，再分別對科倫寧禾增加出資額9000萬元(對應增加科倫寧禾合夥份額9000萬元)、13500萬元(對應增加科倫寧禾合夥份額13500萬元)用於科倫寧禾償還其應付公司的川寧生物股權轉讓款。
此次交易旨在推動川寧生物分拆上市工作，有利於優化川寧生物股東結構及資本結構，增加川寧生物的影響力，促進川寧生物的更好發展，也有利於公司的長遠發展和持續經營，符合全體股東的利益。本次交易完成後，川寧生物仍為公司的控股子公司。此次交易對公司財務狀況和經營成果不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
